Genomic Health

Genomic Health provides genomic information to personalize cancer treatment decisions. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make treatment decisions. The company provides its tissue-based invasive breast, ductal carcinoma in situ (DCIS), prostate and colon Oncotype DX tests as clinical laboratory services, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a gene expression profile expressed as a single quantitative score. The company also provides an Oncotype DX test for patients with DCIS, a pre-invasive form of breast cancer.
  • TickerGHDX
  • ISINUS37244C1018
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for GHDX

ValuEngine Rating and Forecast Report for GHDX

Valens Research

UAFRS vs As Reported Weekly Highlights - 2019 10 31

This week, Valens identified distortions and the corresponding adjustments to correct for those distortions for RDWR, RMAX, and GHDX.

ValuEngine Rating and Forecast Report for GHDX

ValuEngine Rating and Forecast Report for GHDX

Increased risk weighs on GENOMIC HEALTH INCO., penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of GENOMIC HEALTH INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date October 25, 2019, the closing price was USD 67.86 and its target price was estimated at USD 55.07.

ValuEngine Rating and Forecast Report for GHDX

ValuEngine Rating and Forecast Report for GHDX

Valens Research

UAFRS vs As Reported Weekly Highlights - 2019 10 31

This week, Valens identified distortions and the corresponding adjustments to correct for those distortions for RDWR, RMAX, and GHDX.

ValuEngine Rating and Forecast Report for GHDX

ValuEngine Rating and Forecast Report for GHDX

ValuEngine Rating and Forecast Report for GHDX

ValuEngine Rating and Forecast Report for GHDX

Increased risk weighs on GENOMIC HEALTH INCO., penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of GENOMIC HEALTH INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date October 25, 2019, the closing price was USD 67.86 and its target price was estimated at USD 55.07.

ValuEngine Rating and Forecast Report for GHDX

ValuEngine Rating and Forecast Report for GHDX

ValuEngine Rating and Forecast Report for GHDX

ValuEngine Rating and Forecast Report for GHDX

MarketLine Department

Foundation Medicine, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Foundation Medicine, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Foundation Medicine, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitiv...

MarketLine Department

Laboratory Corporation of America Holdings - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Laboratory Corporation of America Holdings Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Laboratory Corporation of America Holdings since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch